Skip to main content
. 2017 May 3;13:603–611. doi: 10.2147/TCRM.S97619

Figure 6.

Figure 6

Reductions in systolic blood pressure are well known to reduce CV risk from multiple studies.

Notes: These three large trials found similar benefits with the caveat that EMPA-REG has an impressive reduction in CV death. This suggests that SGLT2 inhibitors may have multiple mechanisms related to reducing CV events in diabetic patients.

Abbreviations: CV, cardiovascular; SGLT2, sodium-glucose cotransporter 2; SBP, systolic blood pressure.